FOLD - CIK 0001178879
AMICUS THERAPEUTICS, INC. trades as FOLD and has a market capitalization of $4.55 B, making it the #1473 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $634.21M, up 20.0% from the prior year and net income of -$27.11M. This page tracks AMICUS THERAPEUTICS, INC. through 2,171 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 11 fiscal years AMICUS THERAPEUTICS, INC.'s revenue grew from $1.22M to $634.21M, a compound annual growth rate of 76.5%. Net profit margin expanded from -4034.7% to -4.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| 15-12G | - | 2026-05-07 |
| SCHEDULE 13G | - | 2026-05-01 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
| EFFECT | - | 2026-04-29 |
February 20, 2026 16:01 ET
November 04, 2025 07:00 ET
October 23, 2025 07:00 ET
September 08, 2025 09:00 ET
July 31, 2025 07:00 ET
The largest companies sharing AMICUS THERAPEUTICS, INC.'s SEC industry classification (pharmaceutical preparations).
AMICUS THERAPEUTICS, INC. (FOLD) has a market capitalization of $4.55 B as of 2026-06-10, ranking #1473 among US-listed companies.
AMICUS THERAPEUTICS, INC. reported revenue of $634.21M for fiscal year 2025, an increase of 20.0% year over year.
In its latest fiscal year AMICUS THERAPEUTICS, INC. reported a net loss of $27.11M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.